

China's SeekIn gets CE Mark approval for SeekInCare Pan Cancer early detection test

08 March 2022 | News

This first-of-its-kind blood-based pan cancer early detection test combines protein markers, genomic and epigenetic features of cancer in blood



SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, has announced the CE (Conformité Européenne) Mark for SeekInCare Cancer Detection Kit and is now ready to launch this test in European markets.

Nearly 10 million people died from cancer last year worldwide. The majority of cancers is found too late to be treated. Clinically validated cancer early screening tests can save lives, but only cover a few cancer types such as lung, colon, liver, breast, cervix and prostate with limited detection rate and specificity. A single test to effectively screen all cancers has been regarded as the ultimate goal for cancer screening for every person.

SeekIn has an artificial intelligence-based platform that uses insights from both private and public data to identify weak cancer DNA and protein signals in the blood and trace them back to a tissue of origin. SeekIn has patents on the algorithms to reduce background noise and reveal cancer signals in blood.

Dr. Mao Mao, SeekIn's founder and CEO, said "We will continue our efforts to meet additional regulatory requirements in Europe, and to obtain regulatory approvals in the other territories such as China and Japan."